{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T19:32:30Z","timestamp":1777923150761,"version":"3.51.4"},"reference-count":38,"publisher":"SAGE Publications","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Microbial Drug Resistance"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:p>\n                    This study assessed the\n                    <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                    antimicrobial activity of ceftazidime\u2013avibactam (CAZ-AVI) and a panel of comparator agents, including aztreonam, cefepime, ceftazidime, meropenem, imipenem, colistin, piperacillin\u2013tazobactam, and tigecycline against isolates of fluoroquinolone-resistant (FQ-R)\n                    <jats:italic toggle=\"yes\">Klebsiella pneumoniae<\/jats:italic>\n                    collected in 2018 and 2019 from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program. Susceptibility and minimum inhibitory concentration were determined using broth microdilution for all antimicrobial agents by a central reference laboratory according to the Clinical and Laboratory Standards Institute guidelines and European Committee on Antimicrobial Susceptibility Testing guidelines. Of all the\n                    <jats:italic toggle=\"yes\">K. pneumoniae<\/jats:italic>\n                    isolates (\n                    <jats:italic toggle=\"yes\">n<\/jats:italic>\n                    \u2009=\u200910,906), 44.1% (4,814\/10,906) were FQ-R. Of these, 71.3% (3,432\/4,814) were extended-spectrum \u03b2-lactamase (ESBL)-positive, and 10.4% (499\/4,814) were CAZ-AVI-resistant. CAZ-AVI showed high susceptibility (&gt;87%) against all the FQ-R\n                    <jats:italic toggle=\"yes\">K. pneumoniae<\/jats:italic>\n                    isolates. However, metallo- \u03b2-lactamase-positive isolates showed low susceptibility (3.8%; 18\/470) to CAZ-AVI. Among the different geographical regions, CAZ-AVI showed the highest activity against isolates collected from North America (98.2%, 216\/220) and lowest against those collected from Asia Pacific (APAC) (81.7%; 882\/1,079). Among comparator agents, carbapenems showed a relatively lower susceptibility (&lt;71.5%), while only tigecycline and colistin were active (&gt;85%) across all isolates. In conclusion, CAZ-AVI may be a potential treatment option for FQ-R\n                    <jats:italic toggle=\"yes\">K. pneumoniae<\/jats:italic>\n                    isolates. However, increasing CAZ-AVI resistance among ESBL-positive and metallo-\u03b2-lactamase-positive isolates and in isolates from APAC warrants continuous surveillance.\n                  <\/jats:p>","DOI":"10.1089\/mdr.2022.0104","type":"journal-article","created":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T14:31:36Z","timestamp":1666017096000},"page":"1019-1027","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Antimicrobial Activity of Ceftazidime\u2013Avibactam and Comparators Against Fluoroquinolone-Resistant\n                    <i>Klebsiella pneumoniae<\/i>\n                    Collected Globally from Antimicrobial Testing Leadership and Surveillance: 2018\u20132019"],"prefix":"10.1177","volume":"28","author":[{"given":"Pattarachai","family":"Kiratisin","sequence":"first","affiliation":[{"name":"Department of Microbiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis F.","family":"Arhin","sequence":"additional","affiliation":[{"name":"Hospital Business Unit, Pfizer, Inc., Kirkland, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Stone","sequence":"additional","affiliation":[{"name":"Hospital Business Unit, Pfizer, Inc., Groton, Connecticut, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2811-3069","authenticated-orcid":false,"given":"Eric","family":"Utt","sequence":"additional","affiliation":[{"name":"Hospital Business Unit, Pfizer, Inc., Groton, Connecticut, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,11,14]]},"reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.1039\/C9MD00120D"},{"issue":"1","key":"e_1_3_6_3_2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/nyas.12830","article-title":"Mechanisms of drug resistance: Quinolone resistance","volume":"1354","author":"Hooper DC","year":"2015","unstructured":"Hooper DC, , Jacoby GA. Mechanisms of drug resistance: Quinolone resistance. Ann N Y Acad Sci, 2015; 1354(1):12\u201331; doi: 10.1111\/nyas.12830","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"e_1_3_6_4_2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1055\/s-0040-1716478","article-title":"Fluoroquinolone resistance in clinical isolates of Klebsiella pneumonia e","volume":"12","author":"Geetha PV","year":"2020","unstructured":"Geetha PV, , Aishwarya KVL, , Mariappan S, et al. Fluoroquinolone resistance in clinical isolates of Klebsiella pneumonia e. J Lab Physicians, 2020; 12(2):121\u2013125; doi: 10.1055\/s-0040-1716478","journal-title":"J Lab Physicians"},{"issue":"12","key":"e_1_3_6_5_2","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1093\/infdis\/jiv279","article-title":"The rise of fluoroquinolone-resistant Escherichia coli in the community: Scarier than we thought","volume":"212","author":"Spellberg B","year":"2015","unstructured":"Spellberg B, , Doi Y. The rise of fluoroquinolone-resistant Escherichia coli in the community: Scarier than we thought. J Infect Dis, 2015; 212(12):1853\u20131855; doi: 10.1093\/infdis\/jiv279","journal-title":"J Infect Dis"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/976273"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.18.2.306-325.2005"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12941-019-0343-8"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2018.00004"},{"key":"e_1_3_6_10_2","first-page":"168292","article-title":"Comparative analysis of quinolone resistance in clinical isolates of Klebsiella pneumoniae and Escherichia coli from Chinese children and adults","volume":"2015","author":"Huang Y","year":"2015","unstructured":"Huang Y, , Ogutu JO, , Gu J, et al. Comparative analysis of quinolone resistance in clinical isolates of Klebsiella pneumoniae and Escherichia coli from Chinese children and adults. Biomed Res Int, 2015; 2015:168292; doi: 10.1155\/2015\/168292","journal-title":"Biomed Res Int"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2019.12.009"},{"key":"e_1_3_6_12_2","unstructured":"Allergen. Avycaz (ceftazidime\u2013avibactam) for injection for intravenous use: Prescribing information; Allergen; 2018. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/206494s004lbl.pdf [Last accessed: August12 2022]."},{"key":"e_1_3_6_13_2","unstructured":"Pfizer. Zavicefta: Summary of product characteristics. Pfizer; 2018. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zavicefta-epar-product-information_en.pdf [Last accessed: August12 2022]."},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2021.11.025"},{"key":"e_1_3_6_15_2","article-title":"Infectious Diseases Society of America 2022 guidance on the treatment of extended-spectrum beta-lactamase producing enterobacterales (ESBL-E), carbapenem-resistant enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa)","author":"Tamma PD","year":"2022","unstructured":"Tamma PD, , Aitken SL, , Bonomo RA, et al. Infectious Diseases Society of America 2022 guidance on the treatment of extended-spectrum beta-lactamase producing enterobacterales (ESBL-E), carbapenem-resistant enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). Clin Infect Dis, 2022;caic268; doi: 10.1093\/cid\/ciac268","journal-title":"Clin Infect Dis"},{"issue":"6","key":"e_1_3_6_16_2","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1128\/AAC.05136-14","article-title":"Activity of ceftazidime-avibactam against fluoroquinolone-resistant Enterobacteriaceae and Pseudomonas aeruginosa","volume":"59","author":"Pitart C","year":"2015","unstructured":"Pitart C, , Marco F, , Keating TA, et al. Activity of ceftazidime-avibactam against fluoroquinolone-resistant Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother, 2015; 59(6):3059\u20133065; doi: 10.1128\/AAC.05136-14","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_6_17_2","unstructured":"CLSI. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard. 11th ed. CLSI Standard M07. Clinical and Laboratory Standards Institute: Wayne PA; 2020."},{"key":"e_1_3_6_18_2","unstructured":"EUCAST. Breakpoint tables for interpretation of MICs and zone diameters. Version 12.0 2022. Available from: http:\/\/www.eucast.org [Last accessed: May 18 2022]."},{"key":"e_1_3_6_19_2","unstructured":"CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 30th ed. Supplement M100. Clinical Laboratory Standards Institute: Wayne PA; 2018."},{"issue":"6","key":"e_1_3_6_20_2","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1128\/AAC.05186-14","article-title":"Trends in susceptibility of Escherichia coli from intra-abdominal infections to ertapenem and comparators in the United States according to data from the SMART program, 2009 to 2013","volume":"59","author":"Lob SH","year":"2015","unstructured":"Lob SH, , Kazmierczak KM, , Badal RE, et al. Trends in susceptibility of Escherichia coli from intra-abdominal infections to ertapenem and comparators in the United States according to data from the SMART program, 2009 to 2013. Antimicrob Agents Chemother, 2015; 59(6):3606\u20133610; doi: 10.1128\/AAC.05186-14","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.2174\/1874285801206010074"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2014.04.007"},{"issue":"1","key":"e_1_3_6_23_2","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/s12879-020-04981-0","article-title":"Association between the rate of fluoroquinolones-resistant gram-negative bacteria and antibiotic consumption from China based on 145 tertiary hospitals data in 2014","volume":"20","author":"Yang P","year":"2020","unstructured":"Yang P, , Chen Y, , Jiang S, et al. Association between the rate of fluoroquinolones-resistant gram-negative bacteria and antibiotic consumption from China based on 145 tertiary hospitals data in 2014. BMC Infect Dis, 2020; 20(1):269; doi: 10.1186\/s12879-020-04981-0","journal-title":"BMC Infect Dis"},{"issue":"3","key":"e_1_3_6_24_2","doi-asserted-by":"crossref","first-page":"106111","DOI":"10.1016\/j.ijantimicag.2020.106111","article-title":"Assessment of the in vitro activity of ceftazidime\/avibactam against a global collection of multidrug-resistant Klebsiella spp. from the INFORM surveillance programme (2015\u20132017)","volume":"56","author":"Rossolini GM","year":"2020","unstructured":"Rossolini GM, , Stone GG. Assessment of the in vitro activity of ceftazidime\/avibactam against a global collection of multidrug-resistant Klebsiella spp. from the INFORM surveillance programme (2015\u20132017). Int J Antimicrob Agents, 2020; 56(3):106111; doi: 10.1016\/j.ijantimicag.2020.106111","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"e_1_3_6_25_2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12941-020-00355-1","article-title":"In vitro activity of ceftazidime-avibactam and comparators against Gram-negative bacterial isolates collected in the Asia-Pacific region as part of the INFORM program (2015\u20132017)","volume":"19","author":"Ko WC","year":"2020","unstructured":"Ko WC, , Stone GG. In vitro activity of ceftazidime-avibactam and comparators against Gram-negative bacterial isolates collected in the Asia-Pacific region as part of the INFORM program (2015\u20132017). Ann Clin Microbiol Antimicrob, 2020; 19(1):14; doi: 10.1186\/s12941-020-00355-1","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"7","key":"e_1_3_6_26_2","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1093\/jac\/dkaa089","article-title":"In vitro activity of ceftazidime\/avibactam and comparators against Gram-negative bacterial isolates collected from Latin American centres between 2015 and 2017","volume":"75","author":"Stone GG","year":"2020","unstructured":"Stone GG, , Ponce-de-Leon A. In vitro activity of ceftazidime\/avibactam and comparators against Gram-negative bacterial isolates collected from Latin American centres between 2015 and 2017. J Antimicrob Chemother, 2020; 75(7):1859\u20131873; doi: 10.1093\/jac\/dkaa089","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"e_1_3_6_27_2","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1128\/AAC.00163-15","article-title":"Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from U.S. hospitals (2011 to 2013) and characterization of beta-lactamase-producing strains","volume":"59","author":"Castanheira M","year":"2015","unstructured":"Castanheira M, , Mills JC, , Costello SE, et al. Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from U.S. hospitals (2011 to 2013) and characterization of beta-lactamase-producing strains. Antimicrob Agents Chemother, 2015; 59(6):3509\u20133517; doi: 10.1128\/AAC.00163-15","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"e_1_3_6_28_2","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1093\/cid\/ciaa586","article-title":"Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by metallo-beta-lactamase-producing enterobacterales","volume":"72","author":"Falcone M","year":"2021","unstructured":"Falcone M, , Daikos GL, , Tiseo G, et al. Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by metallo-beta-lactamase-producing enterobacterales. Clin Infect Dis, 2021; 72(11):1871\u20131878; doi: 10.1093\/cid\/ciaa586","journal-title":"Clin Infect Dis"},{"issue":"4","key":"e_1_3_6_29_2","doi-asserted-by":"crossref","first-page":"e02243","DOI":"10.1128\/AAC.02243-16","article-title":"Can ceftazidime-avibactam and aztreonam overcome beta-lactam resistance conferred by metallo-beta-lactamases in Enterobacteriaceae?","volume":"61","author":"Marshall S","year":"2017","unstructured":"Marshall S, , Hujer AM, , Rojas LJ, et al. Can ceftazidime-avibactam and aztreonam overcome beta-lactam resistance conferred by metallo-beta-lactamases in Enterobacteriaceae?. Antimicrob Agents Chemother, 2017; 61(4):e02243-16; doi: 10.1128\/AAC.02243-16","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_6_30_2","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jgar.2020.10.016","article-title":"Global genotype distribution of human clinical isolates of New Delhi metallo-beta-lactamase-producing Klebsiella pneumoniae; A systematic review","volume":"23","author":"Safavi M","year":"2020","unstructured":"Safavi M, , Bostanshirin N, , Hajikhani B, et al. Global genotype distribution of human clinical isolates of New Delhi metallo-beta-lactamase-producing Klebsiella pneumoniae; A systematic review. J Glob Antimicrob Resist, 2020; 23:420\u2013429; doi: 10.1016\/j.jgar.2020.10.016","journal-title":"J Glob Antimicrob Resist"},{"issue":"4","key":"e_1_3_6_31_2","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1080\/21505594.2016.1222343","article-title":"The global epidemiology of carbapenemase-producing Enterobacteriaceae","volume":"8","author":"van Duin D","year":"2017","unstructured":"van Duin D, , Doi Y. The global epidemiology of carbapenemase-producing Enterobacteriaceae. Virulence, 2017; 8(4):460\u2013469; doi: 10.1080\/21505594.2016.1222343","journal-title":"Virulence"},{"issue":"1","key":"e_1_3_6_32_2","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1186\/s12879-021-06153-0","article-title":"In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016\u20132018)","volume":"21","author":"Pierard D","year":"2021","unstructured":"Pierard D, , Stone GG. In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016\u20132018). BMC Infect Dis, 2021; 21(1):600; doi: 10.1186\/s12879-021-06153-0","journal-title":"BMC Infect Dis"},{"key":"e_1_3_6_33_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8070934"},{"key":"e_1_3_6_34_2","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S199844"},{"key":"e_1_3_6_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12714"},{"key":"e_1_3_6_36_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12941-019-0339-4"},{"issue":"12","key":"e_1_3_6_37_2","doi-asserted-by":"crossref","first-page":"e23506","DOI":"10.1002\/jcla.23506","article-title":"Molecular epidemiology and mechanisms of tigecycline resistance in carbapenem-resistant Klebsiella pneumoniae isolates","volume":"34","author":"Park Y","year":"2020","unstructured":"Park Y, , Choi Q, , Kwon GC, et al. Molecular epidemiology and mechanisms of tigecycline resistance in carbapenem-resistant Klebsiella pneumoniae isolates. J Clin Lab Anal, 2020; 34(12):e23506; doi: 10.1002\/jcla.23506","journal-title":"J Clin Lab Anal"},{"issue":"7","key":"e_1_3_6_38_2","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00228-015-1865-4","article-title":"A review on colistin nephrotoxicity","volume":"71","author":"Ordooei Javan A","year":"2015","unstructured":"Ordooei Javan A, , Shokouhi S, , Sahraei Z. A review on colistin nephrotoxicity. Eur J Clin Pharmacol, 2015; 71(7):801\u2013810; doi: 10.1007\/s00228-015-1865-4","journal-title":"Eur J Clin Pharmacol"},{"issue":"7","key":"e_1_3_6_39_2","doi-asserted-by":"crossref","first-page":"e0200020","DOI":"10.1128\/AAC.02000-20","article-title":"Epidemiology of carbapenem resistance determinants identified in meropenem-nonsusceptible enterobacterales collected as part of a global surveillance program, 2012 to 2017","volume":"65","author":"Kazmierczak KM","year":"2021","unstructured":"Kazmierczak KM, , Karlowsky JA, , de Jonge BLM, et al. Epidemiology of carbapenem resistance determinants identified in meropenem-nonsusceptible enterobacterales collected as part of a global surveillance program, 2012 to 2017. Antimicrob Agents Chemother, 2021; 65(7):e0200020; doi: 10.1128\/AAC.02000-20","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Microbial Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/mdr.2022.0104","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2022.0104","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2022.0104","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T20:40:26Z","timestamp":1777668026000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/mdr.2022.0104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10.1089\/mdr.2022.0104"],"URL":"https:\/\/doi.org\/10.1089\/mdr.2022.0104","relation":{},"ISSN":["1076-6294","1931-8448"],"issn-type":[{"value":"1076-6294","type":"print"},{"value":"1931-8448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11]]}}}